Specifically, this patient had stage IV PLEKHA6‐NTRK1, MET amplified (fold change: 12.3) cholangiocarcinoma which initially responded and then became resistant to the combination therapy with the TRK inhibitor selitrectinib and the type I MET inhibitor crizotinib. The gene discussed is MET; the disease is cholangiocarcinoma.